- Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
- Day One Announces Sale of Priority Review Voucher for $108 Million
- Day One Reports First Quarter 2024 Financial Results and Corporate Progress
- Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
- Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
- Day One Announces Two New Appointments to Board of Directors
- Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
- Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
More ▼
Key statistics
On Friday, Day One Biopharmaceuticals Inc (DAWN:NSQ) closed at 16.03, -11.29% below its 52-week high of 18.07, set on May 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.14 |
---|---|
High | 16.35 |
Low | 15.79 |
Bid | 13.75 |
Offer | 16.69 |
Previous close | 15.88 |
Average volume | 887.89k |
---|---|
Shares outstanding | 87.39m |
Free float | 70.22m |
P/E (TTM) | -- |
Market cap | 1.40bn USD |
EPS (TTM) | -2.50 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:00 BST.
More ▼